Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs
Net product revenues for the third
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9,
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026.
Correction of MBNL- dependent mis-splicing provides functional evidence that SRP-1003 is degrading disease-causing RNA within the nucleus.
In a preclinical model, SRP-1003 reduced pathogenic DMPK mRNA in both the
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Sarepta Therapeutics,
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of
Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 years compared to
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept.
Recipients include 20 individuals living with Duchenne and five siblings of individuals living with the condition
Now in its ninth year, program has awarded more than 150 scholarships
Sarepta Therapeutics, Inc.
NEW YORK CITY and NEW ORLEANS, Sept. 4, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Sarepta Therapeutics,
New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth
Net product revenues for the second quarter 2026
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta’s 2024
